Additionally, PRO TACs (such as the DD04015 and the DD03171) were developed using a new class of noncovalent BTK inhibitors that effectively degrade the BTKs and slow cancer cell development (Huang et al. 2018; Dobrovolsky et al. 2019). The gene discussed is BTK; the disease is cancer.